You are here: Home » Companies » News
Business Standard

Nektar's R&D facility to come up in Hyd

BS Reporter  |  Chennai/ Hyderabad 

This is company's first R&D facility outside the US.
Nektar Therapeutics, a biopharmaceutical company, is setting up its first research and development centre outside the US at the ICICI Knowledge Park on the outskirts of Hyderabad.
Spread over an extent of 15 acres, the facility would have a built-up area of up to 40,000 square feet. It will have a headcount of 80 to 100 people to start with. Over the last two years, Nektar has been operating here with about 40 employees from a leased facility.
"The Hyderabad facility significantly accelerates Nektar's global R&D," company's president and chief executive officer, Howard Robin, told mediapersons.
He, however, expressed his inability to disclose the quantum of investment being made in the new facility, the foundation stone for which was laid by Andhra Pradesh chief minister, YS Rajasekhara Reddy, on Friday.
Robin said that Nektar's decision to come to India was largely based on the availability of "outstanding number of educated scientists," who could provide R&D output faster, and at a lower cost.
According to Robin, Nektar's pulmonary and PEGylation technology and manufacturing capabilities have enabled nine approved products for partners, which include world's leading pharmaceutical and biotechnology like Pfizer, Novartis and Bayer.
The company has also developed its own products by applying the same technology to existing medicines with the objective of improving efficacy, safety and compliance.
Explaining that Nectar is the world leader in PEGylation technology, he said that every single PEGylated product approved over the last 10 years had been enabled by the company.
PEGylation is adding various structures to molecules to improve efficacy of medicines.

First Published: Mon, May 07 2007. 00:00 IST